Healthcare Royalty HCRX 深 沪
等待开盘 08-03 09:30:00 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 0.00
- 市盈率 静 0.00
- 换手率 0.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Spero inks $105M financing deal with KKR affiliate
Spero Therapeutics (SPRO) said that it secured $105M in non-recourse, non-dilutive financing from affiliates of Healthcare Royalty, a business of KKR (KKR). The proceeds will primarily fund the Phase ...
07-14 18:33
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics announced a $105 million non-recourse, non-dilutive royalty financing transaction with affiliates of Healthcare Royalty (HCRx). The funds will support the Phase 2 development of SP001, Spero's lead immunology drug candidate, licensed from Innovent Biologics. The deal unlocks immediate value from future Utebzi milestones and royalties, enhancing Spero's financial position and enabling long-term commercial upside. Spero updated i...
07-14 10:02
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Nanobiotix reported key milestones in its third quarter 2025 update, including a $71 million non-dilutive royalty financing with HCRx, advancement of JNJ-1900 (NBTXR3) clinical development with esophageal cancer data and Phase 3 study transfer to J&J, and progress in the Curadigm Nanoprimer program. The company expects JNJ-1900 clinical updates in 2026 across melanoma, lung, pancreatic, and esophageal cancers. With €20.4 million in cash and the H...
2025-11-24 21:15
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix has entered into a $71 million royalty-based financing agreement with HealthCare Royalty to extend its cash runway into early 2028. The funding supports development in head and neck cancer and lung cancer, and enables self-sustainability and growth of next-generation nanotherapeutic platforms. HealthCare Royalty will receive a capped portion of milestones and royalties on JNJ-1900 (NBTXR3). The upfront payment is $50 million, with an a...
2025-10-31 07:00
